Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899282021> ?p ?o ?g. }
- W2899282021 abstract "Hyperkalaemia is a common electrolyte abnormality caused by reduced renal potassium excretion in patients with chronic kidney diseases (CKD). Potassium binders, such as sodium polystyrene sulfonate and calcium polystyrene sulfonate, are widely used but may lead to constipation and other adverse gastrointestinal (GI) symptoms, reducing their tolerability. Patiromer and sodium zirconium cyclosilicate are newer ion exchange resins for treatment of hyperkalaemia which may cause fewer GI side-effects. Although more recent studies are focusing on clinically-relevant endpoints such as cardiac complications or death, the evidence on safety is still limited. Given the recent expansion in the available treatment options, it is appropriate to review the evidence of effectiveness and tolerability of all potassium exchange resins among people with CKD, with the aim to provide guidance to consumers, practitioners, and policy-makers.To assess the benefits and harms of potassium binders for treating chronic hyperkalaemia among adults and children with CKD.We searched the Cochrane Kidney and Transplant Register of Studies up to 10 March 2020 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.Randomised controlled trials (RCTs) and quasi-randomised controlled studies (quasi-RCTs) evaluating potassium binders for chronic hyperkalaemia administered in adults and children with CKD.Two authors independently assessed risks of bias and extracted data. Treatment estimates were summarised by random effects meta-analysis and expressed as relative risk (RR) or mean difference (MD), with 95% confidence interval (CI). Evidence certainty was assessed using GRADE processes.Fifteen studies, randomising 1849 adult participants were eligible for inclusion. Twelve studies involved participants with CKD (stages 1 to 5) not requiring dialysis and three studies were among participants treated with haemodialysis. Potassium binders included calcium polystyrene sulfonate, sodium polystyrene sulfonate, patiromer, and sodium zirconium cyclosilicate. A range of routes, doses, and timing of drug administration were used. Study duration varied from 12 hours to 52 weeks (median 4 weeks). Three were cross-over studies. The mean study age ranged from 53.1 years to 73 years. No studies evaluated treatment in children. Some studies had methodological domains that were at high or unclear risks of bias, leading to low certainty in the results. Studies were not designed to measure treatment effects on cardiac arrhythmias or major GI symptoms. Ten studies (1367 randomised participants) compared a potassium binder to placebo. The certainty of the evidence was low for all outcomes. We categorised treatments in newer agents (patiromer or sodium zirconium cyclosilicate) and older agents (calcium polystyrene sulfonate and sodium polystyrene sulfonate). Patiromer or sodium zirconium cyclosilicate may make little or no difference to death (any cause) (4 studies, 688 participants: RR 0.69, 95% CI 0.11, 4.32; I2 = 0%; low certainty evidence) in CKD. The treatment effect of older potassium binders on death (any cause) was unknown. One cardiovascular death was reported with potassium binder in one study, showing that there was no difference between patiromer or sodium zirconium cyclosilicate and placebo for cardiovascular death in CKD and HD. There was no evidence of a difference between patiromer or sodium zirconium cyclosilicate and placebo for health-related quality of life (HRQoL) at the end of treatment (one study) in CKD or HD. Potassium binders had uncertain effects on nausea (3 studies, 229 participants: RR 2.10, 95% CI 0.65, 6.78; I2 = 0%; low certainty evidence), diarrhoea (5 studies, 720 participants: RR 0.84, 95% CI 0.47, 1.48; I2 = 0%; low certainty evidence), and vomiting (2 studies, 122 participants: RR 1.72, 95% CI 0.35 to 8.51; I2 = 0%; low certainty evidence) in CKD. Potassium binders may lower serum potassium levels (at the end of treatment) (3 studies, 277 participants: MD -0.62 mEq/L, 95% CI -0.97, -0.27; I2 = 92%; low certainty evidence) in CKD and HD. Potassium binders had uncertain effects on constipation (4 studies, 425 participants: RR 1.58, 95% CI 0.71, 3.52; I2 = 0%; low certainty evidence) in CKD. Potassium binders may decrease systolic blood pressure (BP) (2 studies, 369 participants: MD -3.73 mmHg, 95%CI -6.64 to -0.83; I2 = 79%; low certainty evidence) and diastolic BP (one study) at the end of the treatment. No study reported outcome data for cardiac arrhythmias or major GI events. Calcium polystyrene sulfonate may make little or no difference to serum potassium levels at end of treatment, compared to sodium polystyrene sulfonate (2 studies, 117 participants: MD 0.38 mEq/L, 95% CI -0.03 to 0.79; I2 = 42%, low certainty evidence). There was no evidence of a difference in systolic BP (one study), diastolic BP (one study), or constipation (one study) between calcium polystyrene sulfonate and sodium polystyrene sulfonate. There was no difference between high-dose and low-dose patiromer for death (sudden death) (one study), stroke (one study), myocardial infarction (one study), or constipation (one study). The comparative effects whether potassium binders were administered with or without food, laxatives, or sorbitol, were very uncertain with insufficient data to perform meta-analysis.Evidence supporting clinical decision-making for different potassium binders to treat chronic hyperkalaemia in adults with CKD is of low certainty; no studies were identified in children. Available studies have not been designed to measure treatment effects on clinical outcomes such as cardiac arrhythmias or major GI symptoms. This review suggests the need for a large, adequately powered study of potassium binders versus placebo that assesses clinical outcomes of relevance to patients, clinicians and policy-makers. This data could be used to assess cost-effectiveness, given the lack of definitive studies and the clinical importance of potassium binders for chronic hyperkalaemia in people with CKD." @default.
- W2899282021 created "2018-11-09" @default.
- W2899282021 creator A5003005836 @default.
- W2899282021 creator A5018429053 @default.
- W2899282021 creator A5035896202 @default.
- W2899282021 creator A5078001075 @default.
- W2899282021 creator A5080193257 @default.
- W2899282021 date "2020-06-26" @default.
- W2899282021 modified "2023-10-04" @default.
- W2899282021 title "Potassium binders for chronic hyperkalaemia in people with chronic kidney disease" @default.
- W2899282021 cites W1756552807 @default.
- W2899282021 cites W1783540914 @default.
- W2899282021 cites W1841081517 @default.
- W2899282021 cites W1905965231 @default.
- W2899282021 cites W1934946546 @default.
- W2899282021 cites W1960944180 @default.
- W2899282021 cites W1970939567 @default.
- W2899282021 cites W1993617109 @default.
- W2899282021 cites W2018721824 @default.
- W2899282021 cites W2041162893 @default.
- W2899282021 cites W2051290728 @default.
- W2899282021 cites W2061000205 @default.
- W2899282021 cites W2089099760 @default.
- W2899282021 cites W2093767567 @default.
- W2899282021 cites W2100169278 @default.
- W2899282021 cites W2102098144 @default.
- W2899282021 cites W2104675861 @default.
- W2899282021 cites W2125435699 @default.
- W2899282021 cites W2126125759 @default.
- W2899282021 cites W2128708293 @default.
- W2899282021 cites W2140678550 @default.
- W2899282021 cites W2142844186 @default.
- W2899282021 cites W2152271789 @default.
- W2899282021 cites W2159428387 @default.
- W2899282021 cites W2160982549 @default.
- W2899282021 cites W2163340573 @default.
- W2899282021 cites W2165010366 @default.
- W2899282021 cites W2169077241 @default.
- W2899282021 cites W2192954951 @default.
- W2899282021 cites W2199250366 @default.
- W2899282021 cites W2202570983 @default.
- W2899282021 cites W2217407415 @default.
- W2899282021 cites W2282202421 @default.
- W2899282021 cites W2318757819 @default.
- W2899282021 cites W2320665025 @default.
- W2899282021 cites W2323589234 @default.
- W2899282021 cites W2324948948 @default.
- W2899282021 cites W2328708589 @default.
- W2899282021 cites W2332427115 @default.
- W2899282021 cites W2399206947 @default.
- W2899282021 cites W2409793208 @default.
- W2899282021 cites W2464384279 @default.
- W2899282021 cites W2466258192 @default.
- W2899282021 cites W2472162555 @default.
- W2899282021 cites W2475129834 @default.
- W2899282021 cites W2587652676 @default.
- W2899282021 cites W2588017662 @default.
- W2899282021 cites W2588389730 @default.
- W2899282021 cites W2588571778 @default.
- W2899282021 cites W2588681363 @default.
- W2899282021 cites W2589678280 @default.
- W2899282021 cites W2593683735 @default.
- W2899282021 cites W2603110444 @default.
- W2899282021 cites W2605412207 @default.
- W2899282021 cites W2613291361 @default.
- W2899282021 cites W2617862217 @default.
- W2899282021 cites W2744929116 @default.
- W2899282021 cites W2751931046 @default.
- W2899282021 cites W2764179054 @default.
- W2899282021 cites W2767434013 @default.
- W2899282021 cites W2768906675 @default.
- W2899282021 cites W2769696378 @default.
- W2899282021 cites W2771048206 @default.
- W2899282021 cites W2789280083 @default.
- W2899282021 cites W2790926030 @default.
- W2899282021 cites W2791646934 @default.
- W2899282021 cites W2792112114 @default.
- W2899282021 cites W2803591266 @default.
- W2899282021 cites W2886906721 @default.
- W2899282021 cites W2887959971 @default.
- W2899282021 cites W2892031176 @default.
- W2899282021 cites W2898908721 @default.
- W2899282021 cites W2899282021 @default.
- W2899282021 cites W2905976139 @default.
- W2899282021 cites W2916841405 @default.
- W2899282021 cites W2949981799 @default.
- W2899282021 cites W2955774108 @default.
- W2899282021 cites W2972966903 @default.
- W2899282021 cites W2989842953 @default.
- W2899282021 cites W3003939618 @default.
- W2899282021 cites W3037178080 @default.
- W2899282021 cites W3048116145 @default.
- W2899282021 cites W3106057250 @default.
- W2899282021 cites W4231812563 @default.
- W2899282021 cites W4235053227 @default.
- W2899282021 cites W4238582943 @default.
- W2899282021 cites W4239243711 @default.
- W2899282021 cites W4244904648 @default.
- W2899282021 cites W4245787175 @default.
- W2899282021 cites W4246455926 @default.